Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis

BACKGROUND: Siponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) modulator recently approved for active secondary progressive multiple sclerosis (SPMS). The immunomodulatory effects of siponimod in SPMS have not been previously described. METHODS: We conducted a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Main Authors: Wu, Qi, Mills, Elizabeth A., Wang, Qin, Dowling, Catherine A., Fisher, Caitlyn, Kirch, Britany, Lundy, Steven K., Fox, David A., Mao-Draayer, Yang
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2020
Assuntos:
Clinical Medicine
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098784/
https://ncbi.nlm.nih.gov/pubmed/31935197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.134251
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares